Detalhe da pesquisa
1.
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.
Breast Cancer Res Treat
; 189(3): 665-676, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34553296
2.
CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.
Cancer Sci
; 99(10): 2045-54, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19016765
3.
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.
J Clin Oncol
; 26(18): 2999-3005, 2008 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-18458039